Bifogade filer
Kurs
+0,55%
Kalender
Est. tid* | ||
2025-11-07 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-08-19 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-22 | - | X-dag ordinarie utdelning SCIB 0.00 SEK |
2025-05-21 | - | Årsstämma |
2025-05-13 | - | Kvartalsrapport 2025-Q1 |
2025-02-25 | - | Bokslutskommuniké 2024 |
2024-12-13 | - | Extra Bolagsstämma 2024 |
2024-11-12 | - | Kvartalsrapport 2024-Q3 |
2024-08-21 | - | Kvartalsrapport 2024-Q2 |
2024-06-14 | - | X-dag ordinarie utdelning SCIB 0.00 SEK |
2024-06-13 | - | Årsstämma |
2024-05-31 | - | Kvartalsrapport 2024-Q1 |
2024-02-22 | - | Bokslutskommuniké 2023 |
2023-11-10 | - | Kvartalsrapport 2023-Q3 |
2023-08-18 | - | Kvartalsrapport 2023-Q2 |
2023-05-19 | - | X-dag ordinarie utdelning SCIB 0.00 SEK |
2023-05-17 | - | Årsstämma |
2023-05-10 | - | Kvartalsrapport 2023-Q1 |
2023-02-13 | - | Bokslutskommuniké 2022 |
2022-11-10 | - | Kvartalsrapport 2022-Q3 |
2022-08-18 | - | Kvartalsrapport 2022-Q2 |
2022-05-19 | - | X-dag ordinarie utdelning SCIB 0.00 SEK |
2022-05-18 | - | Årsstämma |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-02-23 | - | Bokslutskommuniké 2021 |
2021-11-11 | - | Kvartalsrapport 2021-Q3 |
2021-09-07 | - | Extra Bolagsstämma 2021 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-19 | - | X-dag ordinarie utdelning SCIB 0.00 SEK |
2021-05-18 | - | Årsstämma |
2021-05-12 | - | Kvartalsrapport 2021-Q1 |
2021-02-19 | - | Bokslutskommuniké 2020 |
2020-11-12 | - | Kvartalsrapport 2020-Q3 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-06-17 | - | Årsstämma |
2020-05-15 | - | X-dag ordinarie utdelning SCIB 0.00 SEK |
2020-05-05 | - | Kvartalsrapport 2020-Q1 |
2020-04-29 | - | Extra Bolagsstämma 2020 |
2020-02-21 | - | Bokslutskommuniké 2019 |
2019-11-13 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-17 | - | X-dag ordinarie utdelning SCIB 0.00 SEK |
2019-05-16 | - | Årsstämma |
2019-05-10 | - | Kvartalsrapport 2019-Q1 |
2019-02-20 | - | Bokslutskommuniké 2018 |
2018-11-13 | - | Kvartalsrapport 2018-Q3 |
2018-08-20 | - | Kvartalsrapport 2018-Q2 |
2018-05-17 | - | X-dag ordinarie utdelning SCIB 0.00 SEK |
2018-05-16 | - | Årsstämma |
2018-05-09 | - | Kvartalsrapport 2018-Q1 |
2018-02-20 | - | Bokslutskommuniké 2017 |
2017-11-15 | - | Extra Bolagsstämma 2017 |
2017-11-10 | - | Kvartalsrapport 2017-Q3 |
2017-08-18 | - | Kvartalsrapport 2017-Q2 |
2017-05-17 | - | X-dag ordinarie utdelning SCIB 0.00 SEK |
2017-05-16 | - | Årsstämma |
2017-05-10 | - | Kvartalsrapport 2017-Q1 |
2017-02-17 | - | Bokslutskommuniké 2016 |
2016-11-14 | - | Kvartalsrapport 2016-Q3 |
2016-08-19 | - | Kvartalsrapport 2016-Q2 |
2016-05-17 | - | X-dag ordinarie utdelning SCIB 0.00 SEK |
2016-05-16 | - | Årsstämma |
2016-05-13 | - | Kvartalsrapport 2016-Q1 |
2016-02-19 | - | Bokslutskommuniké 2015 |
2015-11-12 | - | Kvartalsrapport 2015-Q3 |
2015-08-20 | - | Kvartalsrapport 2015-Q2 |
2015-05-06 | - | Kvartalsrapport 2015-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
STOCKHOLM, SWEDEN, - December 22, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a request for an appropriate Medicare payment assignment for the Nevisense procedure has been submitted to "National Government Services" (NGS), the Medicare Administrative Contractor with carrier jurisdiction responsibility for New York and several other states.
In July 2021, the American Medical Association (AMA) assigned a Category III CPT[® ]code for the Nevisense melanoma detection test that has been used by providers to report the use since then.
The request was submitted to NGS based on provider usage in the New York region. NGS holds the Medicare contract for New York, Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, Illinois, Minnesota and Wisconsin. A decision regarding rate assignment within NGS may be implemented in one or more of NGS jurisdictions.
"Coverage and payment from CMS are important for new procedures and technology such as ours, so this submission is an important milestone for SciBase and for Nevisense in the U.S.," said Simon Grant, CEO of SciBase. "Establishing a payment rate with NGS represents a significant opportunity for SciBase as they cover several regions with significant potential, which would allow providers to utilize this medically necessary technology in these regions. We believe that Nevisense can play a central role in improving skin cancer detection in the U.S., and especially for the important patient demographic covered by Medicare."
For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com
Certified Advisor:
Vator Securities
Tel: +46 8 580 065 99
Email: ca@vatorsec.se
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on December 22, 2021.
About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.